Nitric oxide (NO) and Duchenne Muscular Dystrophy: NO way to go? - Sorbonne Université
Journal Articles Antioxidants Year : 2020

Nitric oxide (NO) and Duchenne Muscular Dystrophy: NO way to go?

Abstract

The discordance between pre-clinical success and clinical failure of treatment options for Duchenne Muscular Dystrophy (DMD) is significant. The termination of clinical trials investigating the phosphodiesterase inhibitors, sildenafil and tadalafil (which prolong the second messenger molecule of nitric oxide (NO) signaling), are prime examples of this. Both attenuated key dystrophic features in the mdx mouse model of DMD yet failed to modulate primary outcomes in clinical settings. We have previously attempted to modulate NO signaling via chronic nitrate supplementation of the mdx mouse but failed to demonstrate beneficial modulation of key dystrophic features (i.e., metabolism). Instead, we observed increased muscle damage and nitrosative stress which exacerbated MD. Here, we highlight that acute nitrite treatment of human DMD myoblasts is also detrimental and suggest strategies for moving forward with NO replacement therapy in DMD.
Fichier principal
Vignette du fichier
antioxidants-09-01268.pdf (1.04 Mo) Télécharger le fichier
Origin Publication funded by an institution

Dates and versions

hal-03276089 , version 1 (01-07-2021)

Licence

Identifiers

Cite

Cara A. Timpani, Kamel Mamchaoui, Gillian Butler-Browne, Emma Rybalka. Nitric oxide (NO) and Duchenne Muscular Dystrophy: NO way to go?. Antioxidants , 2020, 9 (12), pp.1268. ⟨10.3390/antiox9121268⟩. ⟨hal-03276089⟩
39 View
39 Download

Altmetric

Share

More